Peptide Help USA is an independent educational resource about peptide therapy and GLP-1 medications in the United States. We don’t run a clinic, sell products, or prescribe anything. Because peptides sit squarely in what Google calls “Your Money or Your Life” territory — content that can affect a reader’s health or finances — we hold ourselves to a higher standard than a typical wellness blog. This page lays out exactly how we work, so you can decide how much weight to give what you read here.
What this site is — and isn’t
Everything published here is general education, not personalized medical advice. We explain what compounds are, what the research does and doesn’t show, what the current US legal landscape looks like, and how legitimate access routes work. We do not diagnose, treat, or recommend a course of therapy for any individual.
Nothing on the site creates a doctor-patient relationship, and reading it is no substitute for a consultation with a licensed clinician who knows your history. The clinical scope, liability limits, and emergency guidance live in our medical disclaimer; this page is about process — how the words on each page get made.
Note: If a page ever reads to you like instructions for sourcing or self-administering a peptide, we’ve failed our own standard. Tell us via the contact page and we’ll fix it.
How we research a page
Every substantive page starts with primary-source research, not by paraphrasing other content sites. For the topics that matter most — legal status, FDA actions, and pricing — we go to the original record:
- Regulatory status is checked against the FDA’s published 503A bulk drug substances list, Federal Register notices, and Pharmacy Compounding Advisory Committee (PCAC) scheduling — not against secondhand summaries, which frequently overstate what has actually happened.
- Evidence claims are grounded in the published literature. Where the human evidence for a peptide is thin or limited to animal studies, we say so plainly rather than implying a settled benefit.
- Pricing reflects real, current US ranges from telehealth programs, compounding pharmacies, and clinics — described as ranges, because they move and vary by provider.
We treat research-note shorthand and aggregator articles as leads to verify, never as facts to repeat. When a source and the primary record disagree, the primary record wins.
How we handle a fast-moving 2026 landscape
US peptide regulation changed materially in 2026, and it is still changing. As of this writing, roughly a dozen peptides have been removed from the FDA’s Category 2 “do not compound” list, with a PCAC review scheduled for July 23–24, 2026 to consider whether specific substances should be added to the 503A bulks list. Crucially, removal from Category 2 is not the same as approval, and it is not the same as a Category 1 placement — formal rulemaking is still pending, and no peptide has completed that path.
Because of this, we frame regulatory content as current as of the page’s last-updated date and still in motion, rather than presenting any outcome as final. We’d rather a page read as cautious and accurate than confident and wrong. The deep dive on this sits at the 2026 FDA peptide reclassification, and the broader question is covered at are peptides legal in the US?.
Our compliance lines — what we will not do
These are non-negotiable, and they apply to every page regardless of how high-intent the search query is:
- No dosing protocols. We don’t publish specific milligram amounts, injection frequencies, or titration ladders. Most compounds people search for are not FDA-approved and are obtained gray-market, where actual vial content is unverified; a “standard” internet dose applied to an unknown product is unsafe. We explain how dosing is decided and why fixed protocols are dangerous, never the numbers themselves.
- No sourcing instructions. “How to get X” pages describe legitimate routes — telehealth evaluation, a 503A compounding prescription, a clinic visit — not where to buy unregulated product.
- No invented proof. We don’t publish fabricated testimonials, before/after claims presented as fact, or “guaranteed results.”
- No fake specifics. Location pages describe how local access works; they never list invented clinic names, addresses, or phone numbers.
When research surfaces a genuine safety concern — gray-market purity risk, or a compound with a notable adverse profile — we state it directly rather than soften it.
What we cover — and where we stop
Our remit is the practical, US-specific questions people actually have: what a peptide is, what the evidence quality looks like, its current legal and FDA status, realistic cost ranges, and the legitimate routes to access it. We also cover GLP-1 medications and the local picture in specific US cities and states.
There are questions we deliberately leave to a clinician. We won’t tell you whether a given peptide is right for your body, what it should do at a particular dose, or how to combine compounds. Those are individualized medical decisions, and a public web page is the wrong place to make them. When a topic crosses from “here’s how this works in general” into “here’s what you personally should do,” we hand off to the recommendation that you speak with a licensed provider.
How we link
Internal links connect related topics so you can follow a question to its fuller answer — the legal status pages, the access pages, the cost pages. External links, where we use them, point to primary sources or reputable references rather than to vendors selling unregulated product. We don’t link out to gray-market sellers, and we don’t present a third-party site as endorsed simply because we’ve linked it for context.
How content is written and reviewed
Drafting combines editorial expertise with AI-assisted research tools. We’re transparent about that: AI helps us structure and draft, but it does not get the final word. Every page is fact-checked against the primary sources above and reviewed by our editorial team before it goes live. AI assistance never sets our compliance lines and never replaces verification — if a claim can’t be sourced, it doesn’t get published.
We write in US English and US conventions throughout (ZIP codes, 503A/503B, telehealth, anti-aging) because our audience is American.
How we keep pages current
Each page carries a visible last-updated date. We revisit content when the facts underneath it change — a new FDA action, a shift in compounding status, a meaningful move in typical pricing — and re-verify against primary sources rather than lightly editing around the edges. A material change to a page’s substance updates its date; cosmetic fixes don’t.
Given how quickly the 2026 regulatory picture is evolving, the legal and access pages are the ones we monitor most closely.
Corrections and feedback
We’d rather be corrected than be wrong. If you spot an error, an out-of-date figure, or something that reads as non-compliant, let us know through the contact page. We’ll check it against current primary sources and either correct it — reflecting the change in the last-updated date — or explain why we believe the existing version is accurate. We treat reader corrections as a feature of doing YMYL content responsibly, not a nuisance.
Independence and transparency
We are independent and do not sell, supply, or prescribe peptides or GLP-1 medications. Some pages may contain affiliate or referral links to third-party services; where they do, that relationship is disclosed and never changes our editorial judgment about what to recommend you verify before choosing a provider. How we handle your data when you contact us or use our forms is covered in our privacy policy, and the terms governing use of the site are in our terms of use.
For more on who we are and why we built this, see our about page.
Frequently asked questions
Does Peptide Help USA give medical advice?
No. Everything here is general education. We don't run a clinic, prescribe, or treat patients, and nothing on the site creates a doctor-patient relationship. For decisions about your own health, talk to a licensed clinician. See our medical disclaimer for the full statement.
Why doesn't the site publish peptide dosing protocols?
Most peptides people search for are not FDA-approved and are obtained gray-market, where vial concentration and purity are unverified. A fixed mg-and-frequency protocol on a public page is, in practice, self-injection instructions for an unregulated product. We treat dosing as a topic — how it's decided and why fixed internet protocols are unsafe — never as a copyable recipe.
How do you keep the regulatory information current?
US peptide regulation is moving fast in 2026. We verify legal and FDA-status claims against primary sources — the FDA's 503A bulk substances list, Federal Register notices and PCAC scheduling — before publishing, and we date-stamp each page. We frame the current picture as in motion, not finalized, because formal rulemaking is still pending.
Is the site funded by clinics or supplement sellers?
We're independent and don't sell, supply or prescribe peptides. Where a page contains an affiliate or referral link, that relationship never changes our editorial judgment or what we recommend you verify before choosing a provider. Any such relationships are disclosed.
Do you use AI to write content?
We use AI tools as part of drafting and research, but every page is structured, fact-checked against primary sources, and reviewed by our editorial team before publishing. AI assistance never substitutes for verification, and it never sets our compliance lines.
How do I report an error or request a correction?
Use our contact page. If you flag something inaccurate or out of date, we'll check it against current primary sources and correct it — or explain why we believe the existing version is right. Material corrections are reflected in the page's last-updated date.